Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GPX4 | P36969 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6031483 | 0.98 | ALDH1A1 (0.57) | ALDH1A1HTTSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL27270658 | 0.92 | ALDH1A1 (0.52) | ALDH1A1HTTSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL8978116 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL11844730 | 0.87 | — | — | |
| SCHEMBL9279972 | 0.87 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL11023000 | 0.82 | TDP1 (0.48) | ALDH1A1HTTSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL23194425 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL5693136 | 0.81 | ALDH1A1 (0.59) | ALDH1A1HTTSMN1; SMN2POLBCYP1A2 | |
| SCHEMBL10466478 | 0.81 | ALDH1A1 (0.64) | ALDH1A1HTTSMN1; SMN2POLBLMNA | |
| SCHEMBL11291866 | 0.79 | TDP1 (0.50) | ALDH1A1HTTSMN1; SMN2POLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022272133-A2 | PROTEIN STABILIZING COMPOUNDS CONTAINING USP7 LIGANDS | Stablix, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-109336828-B | Quinazoline derivative and preparation method and application thereof | 雅安职业技术学院 | 2022-04-26 | — | — | CN | disclosed |
| EP-3489226-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3091984-B1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | THE J DAVID GLADSTONE INST A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J DAVID GLADSTONE (US) | 2020-04-22 | — | — | EP | disclosed |
| US-10611741-B2 | Substituted benzoxazine and related compounds | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3489226-A1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | Lexicon Pharmaceuticals, Inc. (US) | 2019-05-29 | — | — | EP | disclosed |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | NANOSYN INC. | 2019-04-11 | — | — | US | disclosed |
| EP-2925735-B1 | INHIBITORS OF SODIUM GLUCOSE COTRANSPORTER 1 | LEXICON PHARMACEUTICALS INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2928869-B1 | 1-PHENYL-2-PYRIDINYL ALKYL ALCOHOL DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS | CHIESI FARM SPA (IT) | 2019-02-20 | — | — | EP | disclosed |
| US-10106569-B2 | Inhibitors of sodium glucose transporter 1 for constipation | LEXICON PHARMACEUTICAL, INC. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20070149810-A1 | Vitamin d receptor modulators | ELI LILLY AND COMPANY (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | HOFFMANN-LA ROCHE INC. | 2007-02-01 | — | — | US | disclosed |
| EP-1716123-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005075437-A1 | PYRIDAZINONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| EP-0061709-B1 | 5,6-DIHYDRO-11-ALKYLENE-MORPHANTRIDIN-6-ONES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | BASF Aktiengesellschaft (DE) | 1985-06-05 | — | — | EP | disclosed |
| US-4405623-A | HYPOTENSIVE AGENTS, VASODILATORS | MASAYUKI ISHIKAWA (JP) | 1983-09-20 | — | — | US | disclosed |
| US-4399139-A | ANTIULCER | BASF AKTIENGESELLSCHAFT (DE) | 1983-08-16 | — | — | US | disclosed |
| EP-0061709-A1 | 5,6-Dihydro-11-alkylene-morphantridin-6-ones, process for their preparation and pharmaceutical preparations containing them | BASF Aktiengesellschaft (DE) | 1982-10-06 | — | — | EP | disclosed |
| EP-0040793-A1 | Novel quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof | Ishikawa, Masayuki (JP) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | ALDH1A1 639/4885HTT 2011/4885SMN1; SMN2 4428/4885 |
| US-10106569-B2 | Inhibitors of sodium glucose transporter 1 for constipation | SLC5A1, SLC5A2, SLC10A2 | ALDH1A1 625/4885HTT 2011/4885SMN1; SMN2 1882/4885 |
| US-20070027163-A1 | Indol-3-y-carbonyl-piperidin and piperazin-derivatives | AVPR1A, AVPR2, OXTR | ALDH1A1 1370/4885HTT 741/4885SMN1; SMN2 4271/4885 |
| US-20070149810-A1 | Vitamin d receptor modulators | VDR, CYP2R1, CYP24A1 | ALDH1A1 2594/4885HTT 4219/4885SMN1; SMN2 4873/4885 |
| US-10611741-B2 | Substituted benzoxazine and related compounds | ABCG2, XDH, CYP3A5 | ALDH1A1 367/4885HTT 1626/4885SMN1; SMN2 3014/4885 |
| US-20190106394-A1 | SUBSTITUTED BENZOXAZINE AND RELATED COMPOUNDS | CYP4B1, XDH, UGT2B7 | ALDH1A1 263/4885HTT 1858/4885SMN1; SMN2 1573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.